

Press Release

Studies indicate that VivoSight OCT reliably predicts tumour margins

Thursday, 17 January 2013

Accurate determination of tumour margins is vital to the successful treatment of skin cancer patients. This is especially the case for patients undergoing Mohs Micrographic Surgery where complete tumour removal may require repeated invasive procedures.

Recent studies conducted in two US Healthcare facilities used the VivoSight OCT scanner, manufactured in the UK by Michelson Diagnostics Ltd, to prospectively refine clinically estimated tumour margins prior to Mohs Micrographic Surgery.

The first 52 patient study¹ conducted by Professor Dan Seigel (Department of Dermatology, State University of New York Downstate Medical Center, Brooklyn, New York) concluded that:

“OCT assessment has the potential to reduce the excised area without compromising the integrity of tumour-free borders.”

The second, a case study² of a patient with very ill defined margins concluded that:

“High-resolution imaging with a multi-beam OCT device can accurately predict tumour margins of a BCC prior to Mohs Micrographic Surgery” and went on to say “with any tumour, particularly ill-defined ones, the use of OCT could potentially reduce the number of stages required to clear the tumour leading to shorter operative times and reduction of cost.”

Dr Gertraud Kraehn-Senftleben, a member of the German Onkoderm Network, and one of the first clinicians to use the VivoSight OCT scanner in routine clinical practice commented:

“These studies reflect the day to day experience in our clinic. We routinely scan tumour margins prior to Micrographic Surgery and our experience of more than 150 patients is that it reduces the amount of repeat surgery required. This is a great benefit for both the patient and the Dermatologist”

References

1. Wang, K. X., Meekings, A., Fluhr, J. W., McKenzie, G., Lee, D. A., Fisher, J., Markowitz, O. and Siegel, D. M. (2013), Optical Coherence Tomography–Based Optimization of Mohs Micrographic Surgery of Basal Cell Carcinoma: A Pilot Study. *Dermatologic Surgery*. doi: 10.1111/dsu.12093
2. Chan, C.S., Roher, T.E., (2012), Optical Coherence Tomography and Its Role in Mohs Micrographic Surgery: A Case Report. doi.10.1159/000346237

Press Release

For further information please contact;

Ola Olarimi
Michelson Diagnostics Ltd
1 Grays Farm Production Village
Grays Farm Road
Orpington, Kent BR5 3BD
United Kingdom
t: +44 (0) 208 308 1695, e: ola.olarimi@vivosight.com

Notes to editors

About Michelson Diagnostics

Michelson Diagnostics is a rapidly growing medical device company which has developed and brought to market a scanning device used to improve and accelerate care for patients suffering from non-melanoma skin cancer. Michelson Diagnostics' core product - the VivoSight® OCT scanner - is used by dermatologists to see below the surface of the patient's skin, allowing them to gather additional information about their patient's condition, and is the first of its kind available to dermatologists. Founded in 2006, Michelson Diagnostics designs highly innovative instruments using multi-beam optical coherence tomography solutions. The company is headquartered in Kent, England.

Further information about Michelson Diagnostics is available on the Internet at www.michelsondiagnostics.com or by email to enquiries@vivosight.com.

About Octopus Investments

(www.octopusinvestments.com) Octopus Investments, founded in 2000, is a leading investment specialist. We offer innovative core and satellite investment solutions to UK investors, and a wide range of funding options for exceptional companies.

Our core investments include a discretionary management service and a range of multi-manager multi-asset OEICs. These are complemented by our range of satellite solutions, including venture capital trusts, enterprise investment schemes and inheritance tax products. Each product has been designed to solve specific problems faced by financial advisers and their clients.

Our funding solutions cover the entire capital structure, from equity through mezzanine to senior debt, and we seek out outstanding management teams in unlisted companies with whom we can partner.

Octopus has built its business around three core pillars: customer led innovation, excellence in customer service and the quality of our people. We employ more than 200 people and currently have more than £2.5 billion in assets under management.

Press Release

Octopus has won a number of awards for its products and customer service. We have twice been voted one of the best 100 SMEs to work for by the Sunday Times, and we are one of only two fund management companies to be AAA rated by financial advisers for customer service."

Octopus Media Enquiries:

Georgina Turner, Octopus Investments

t: +44 (0) 207 776 3180, e: GTurner@octopusinvestments.com